Clinical trials: Recurrent Hepatocellular Cancer
Hepotacellular Carcinoma
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
This study is for patients with early-stage liver cancer who are planning to have surgery. The goal of this research is to see if a personalized treatment plan, guided by a computer model (an artificial intelligence tool), can…
- Trial name
- NCT07282184
- Testing
- Neoadjuvant HAIC + Lenvatinib + PD-1 Inhibitor, Curative Liver Resection, Multimodal AI Risk Stratification
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test
In this study, investigators aim to find out how plasma 5hmC level changes in hepatocellular carcinoma patients after liver resection, and determine whether 5hmC can be used as a biomarker for HCC recurrence monitoring.
- Trial name
- NCT03493763
- Testing
- 5hmC profile in plasma cell-free DNA after liver resection
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Neoplasms
Impact of Blood Salvage Therapy on Outcomes After Oncologic Liver Surgery
A before and after trial comparing the systematic use of blood salvage therapy with leucocyte filter during oncologic liver resections.
- Trial name
- NCT05164406
- Testing
- Blood salvage therapy
- Where
- Canada
- Volunteers
- 106 people
- Sponsor
- Université de Sherbrooke
Hepatocellular Carcinoma, Liver Cancer
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation…
- Trial name
- CheckMate 9DX (NCT03383458)
- Testing
- Nivolumab
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 545 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00956930
- Testing
- yttrium Y 90 glass microspheres, Doxorubicin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
HCC
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
ctDNA-based liquid biopsy can better detect the presence of MRD before imaging and serological markers, and is suitable for postoperative MRD and recurrence monitoring, which has been clinically validated in several cancer types…
- Trial name
- NCT05458115
- Testing
- Liver resection
- Volunteers
- 200 people
- Sponsor
- Anhui Provincial Hospital
Recurrent Hepatocellular Carcinoma, Lenvatinib
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage.
- Conditions
- Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation
- Trial name
- NCT06609850
- Testing
- TACE, Ablation, Lenvatinb
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
This retrospective observational study aims to evaluate whether artificial intelligence (AI) models can predict aggressive recurrence in patients who underwent liver resection for early-stage hepatocellular carcinoma (HCC).
- Trial name
- NCT07030842
- Testing
- liver resection
- Where
- China
- Volunteers
- 579 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma Recurrent, Hepatocellular Carcinoma
Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
The goal of this observational study is to investigate the effect of non-selective beta-blocker (NSBB) on the recurrence of hepatocellular carcinoma (HCC) following liver transplantation in patients who underwent liver…
- Trial name
- NCT06233708
- Testing
- Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use
- Volunteers
- 2,092 people
- Sponsor
- Asan Medical Center
HCC
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC).
- Trial name
- NCT06420440
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Chen Xiaoping
Hepatitis B Virus, Hepatocellular Carcinoma
TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in China, and approximately 90% of the patients with HCC are also infected with hepatitis B virus (HBV).
- Trial name
- TACE (NCT00960518)
- Testing
- adefovir, TACE
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Tongji University
Liver Cancer
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01011010
- Testing
- doxorubicin hydrochloride, mitomycin C, sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
The purpose of the study is to observe the effect of sorafenib combined with aspirin in preventing the recurrence in high-risk patients with hepatocellular carcinoma.
- Trial name
- NCT02748304
- Testing
- control, sorafenib, aspirin
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Liver Cancer
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer.
- Trial name
- NCT00012324
- Testing
- doxorubicin hydrochloride, nolatrexed dihydrochloride
- Where
- 42 sites in United States, Canada and 1 more
- Sponsor
- Eximias Pharmaceutical
Hepatocellular Carcinoma
Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation
Liver transplantation is the standard treatment for patients with early-stage Hepatocellular Carcinoma (HCC). Currently, important treatment decisions, like the selection of patients for transplantation, are made on crude, static…
- Trial name
- PETMRIinHCC (NCT03839706)
- Testing
- PET MRI
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with…
- Trial name
- NCT07522411
- Testing
- FOLFOX regimen, Immunotherapy, targeted therapy
- Volunteers
- 100 people
- Sponsor
- BinYong Liang
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well dasatinib works in treating patients with advanced liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00459108
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
HCC - Hepatocellular Carcinoma, Adjuvant Treatment
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk
- Trial name
- NCT06958484
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant.
- Conditions
- Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05103904
- Testing
- Laboratory Biomarker Analysis, Lenvatinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University